Navigation Links
Personalized Medicine - The Genomic Revolution in Cardiac Care
Date:9/19/2007

WASHINGTON, Sept. 19 /PRNewswire-USNewswire/ --The Richard B. and Lynne V. Cheney Cardiovascular Institute and The Catherine Birch McCormick Genomics Center at The George Washington University host a cutting edge Symposium to examine the issues and implications around the growing forces of genomics and personalized medicine in cardiology. This symposium is intended to provide a valuable state-of-the-art update on the current status and future directions of the genomics of atherosclerotic cardiovascular disease, heart failure and cardiac arrhythmias, and the potential application to individualizing prevention, diagnosis and treatment for cardiac patients.

The practice of cardiovascular care has seen significant advances in the past 40 years with dramatic reduction of mortality from heart disease. Despite this major progress, cardiovascular disease remains the number one cause of death in the United States and is on the rise in developing countries. As we enter the 21st century there is much more we need to learn about the individualized patient disease susceptibility, progression, and treatment strategies. Medical molecular genetics is the next frontier with the potential to make dramatic breakthroughs in the prediction of disease and improvement of prevention, treatment, and quality of care.

The symposium agenda features luminaries in the field of genomics who will explore the state of cardiovascular genomics and how it relates to clinical practice. Keynote speakers include Elizabeth Nabel, MD, Director, National Heart, Lung, and Blood Institute to address: Genomics & Coronary Artery Disease, and Andrew Plump, MD, Ph.D., Director of Clinical Molecular Profiling, Merck & Co., to discuss: Genomics for Developing Biomarkers. The symposium provides a unique forum in its roster of prestigious speakers from academic, government and industry and in its ability to examine the issues and stimulate new ideas around personalized medicine as it relates to p
'/>"/>

SOURCE The Cheney Cardiovascular Institute
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
2. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
3. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
4. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
6. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
9. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
10. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
11. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)... Results reveal most respondents against expandin... , , LITTLE FALLS, N.J., Nov. 25 /PRNewswi...statin may lower the cardiovascular risk of health...iversal statin use in older adults, according to a...ome 1,212 participants took part in the online pol...
(Date:11/25/2008)... SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire...daq: PARD ), a biopharmaceutical company focused...y that it will be exploring,strategic alternative...o allow,the Company to focus its resources on the...duct candidate, and to support the initial commerc...
(Date:11/25/2008)... 200 Patients Enrolled in Clinical Trial to Asses...ard of Care Therapies for Unresectable Hepatocellu... Light Sciences Oncology, Inc. (LSO...a global Phase 3 clinical trial of Light Infusion ...able hepatocellular carcinoma (HCC), also known as...
(Date:11/24/2008)... DEERFIELD, Ill., and OSAKA, Japan, Nov. 24 /PRNe...nd its wholly-owned subsidiary, Takeda Global Rese...ed today that the Arthritis Advisory Committee of ...ended that the FDA approve febuxostat for the tre... vote was 12 to zero in favor of approval, with on...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3In promiscuous antelopes the battle of the sexes gets flipped 1380 1In promiscuous antelopes the battle of the sexes gets flipped 1380 2Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 1Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 2Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 3Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 4Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 5Diabetes Response Service Launches in U S and Canada 7201 1Diabetes Response Service Launches in U S and Canada 7201 2Experts Available to Discuss World AIDS Day HIV AIDS Issues Facing America 7196 1Experts Available to Discuss World AIDS Day HIV AIDS Issues Facing America 7196 2
...2007 - In a late-breaker,presentation at the 42nd ... Study of the Liver (EASL), researchers today pres...PROVE 1 clinical trial,which is the first trial t...gational hepatitis C protease inhibitor telaprevir...feron (peg-IFN) and,ribavirin (RBV) in treatment-n...
...- ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP) presented... at the American Association of Cancer Research,(A...e that,indibulin has distinct biologic and molecul...d strongly suggest a very different,toxicity profi...thy. While indibulin binds to tubulin in general, ...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 2ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 3
(Date:12/1/2008)...SHINGTON, Dec. 1 Democr... issued the following statement commemorating Worl...go: http://www.newscom.com/cgi-bin/prnh/20080519/... first World AIDS Day, and while we have made stri...pidemic with both a national and global strategy. ...
(Date:12/1/2008)...W ROCHELLE, N.Y., Dec. 1 Due to th...tion in the field of AIDS/HIV research and clinica...ll provide complimentary access to all archival on... the end of December in honor of World AIDS Day. F...Care and STDs ( www.liebertpub.com/apc ) and A...
(Date:12/1/2008)...IRFAX, Va., Dec. 1 The ...y named Julia E. Bradsher, Ph.D., as its new CEO, ...ing. , , Dr. Bradsher brings to FAAN extens...y fatal allergic reaction. For the past six years,...eting team and strategic planning for all Dey Phar...
(Date:12/1/2008)...robic workouts may prevent cognitive decline in so...hDay News) -- Older adults who exercise regularly...ssels in the brain, a new study shows. , The Un...o be presented Monday at the Radiological Society ..., may help explain other studies that exercise pre...
Breaking Medicine News(10 mins):Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2Health News:FAAN Names New CEO 2
...leader in genome-derived vaccines, announced today...ne // candidate (TuliVaxTM) that confers protectiv...considered to be one of the most dangerous potenti...ect was funded by a BioDefense Small Business Inno...
...at Karolinska Institutet have discovered a heretof...ther its blood vessels.// New blood vessels are f...ing vessel. These shoots lengthen, branch off and ...municating networks of channels. The process is ca...
... analysis on chromium picolinate published in the ...ics, confirmed that chromium picolinate is //effec... lipid levels in people with type 2 diabetes. The...hromium picolinate, supports the consistent benefi...
...ing initiative by Sir Richard Branson has received...s was welcomed by the doctors and scientific commu...cial as it sounds. The human blood extracted from...ord blood. This can be collected before the placen...
Other Medicine News:Health News:Rhode Island Biotechnology Company Develops Tularemia Vaccine 2Health News:How Bloods Vessels are Linked Together? 2Health News:Chromium Picolinate Effective for Diabetes Care 2Health News:Chromium Picolinate Effective for Diabetes Care 3
...e HI VISION 8500 diagnostic ultrasound scanner com... operation for exceptional imaging and functionali...anced techniques for image enhancement and control...nding, wideband pulse-inversion, tissue harmonics,...
... a 2.4mm channel within a 12.1mm insertion tube. ...ultrasound image for improved reliability, an elec... and a 7.5 and 5.0mhz transducer for deeper ultras...or anatomical orientation and vascular evaluation ...
...CTRA 1400C are designed to achieve low daily opera...This system includes automated primary tube sampli...says in a single setup. It also has an integrated ...nce curves and patient sample dilutions to ensure ...
The ACL 7000 coagulation analyzer is the right choice for any laboratory that needs a full range of testing capabilities in a cost-effective system. You'll have access to a broad test menu including
Medicine Products: